Biopharma firm Pharvaris' Q3 cash at €329 mln, progressing with Phase 3 trials

Pharvaris NV

12/11/2025 11:59

Overview

Pharvaris reports cash and equivalents of €329 mln as of September 30, 2025

Company progressing with pivotal Phase 3 trials, data expected in 4Q2025 and 2H2026

Pharvaris initiates CREAATE study for AAE-C1INH, expanding clinical focus

Outlook

Pharvaris expects RAPIDe-3 topline data in 4Q2025

CHAPTER-3 topline data anticipated in 2H2026

Company initiated CREAATE study for AAE-C1INH treatment

Result Drivers

R&D - Expenses were €29.8 million for the quarter ended September 30, 2025, compared to €25.8 million for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-EUR 0.60


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Pharvaris NV is $32.50, about 25.8% above its November 11 closing price of $24.12

Press Release: ID:nGNX4MxdDw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)